Sutro Biopharma, Inc.

As of March 18, 2021, Sutro Biopharma, Inc. is considered overvalued and risky due to significant financial distress, reflected in poor valuation metrics and a year-to-date stock decline of 50.93%, compared to the S&P 500's positive return of 12.22%.

As of March 18, 2021, Sutro Biopharma, Inc. is considered overvalued and in financial distress, with poor valuation metrics compared to peers and a year-to-date stock return of -56.59%.

As of June 13, 2025, Sutro Biopharma, Inc. is in a bearish trend with moderate strength, indicated by bearish signals from moving averages, MACD, and Bollinger Bands, despite a mildly bullish weekly KST, and has underperformed the S&P 500.

As of March 2022, the management team of Sutro Biopharma, Inc. includes Chairman Connie Matsui, CEO William Newell, and Directors James Panek, Daniel Petree, Jon Wigginton, Michael Dybbs, and John Freund. They oversee the company's strategic direction and operations.

Sutro Biopharma, Inc. is a clinical stage company focused on developing protein therapeutics for cancer and autoimmune disorders. As of March 2025, it reported net sales of $17 million and a net loss of $76 million, with a market cap of $66.73 million.

As of Jun 18, Sutro Biopharma, Inc. has a market capitalization of 66.73 million, with net sales of 66.44 million and a net profit of -245.22 million over the last four quarters. The company's shareholder's funds are 44.60 million, and total assets are 387.21 million.